Key result
COVID-19 infection is linked to ~395% higher in-hospital mortality in ACS patients undergoing PCI.
Why the study?
The effect of COVID-19 on the in-hospital outcomes of PCI in patients with ACS was not well established.
Does COVID-19 infection worsen in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Meta-Analysis (n=23,225)
Does COVID-19 infection worsen in-hospital outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention?
Odds Ratio: 4.95 (95% CI 3.92–6.36)
p-value: p=<0.01
COVID-19 infection in ACS patients undergoing PCI is associated with a nearly 5-fold higher odds of in-hospital mortality and worse angiographic outcomes.
Heightened mortality risk in COVID-positive ACS-PCI patients warrants clinical vigilance; leaves open whether targeted strategies improve outcomes.
We aimed to study the effect of COVID-19 on the in-hospital outcomes of percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). A systematic literature search was performed in 2nd February 2022 updated in 12th December 2022 for recruiting relevant papers. The effect size was computed via the odds ratio (OR) for dichotomous data or standardized mean difference (SMD) for continuous data along with the 95% confidence interval (95%CI). After the screening of 1075 records, we found 11 relevant papers that included 2018 COVID-19 patients and negative controls 21207. ACS patients with COVID-19 had a significant higher mortality rate (OR: 4.95; 95%CI: 3.92-6.36; p <0.01), long hospital stay (days) 19 (SMD: 1.17; 95%CI: 0.92-1.42; p <0.01) and reduced post TIMI 3 score (OR: 0.55; 95%CI: 0.41-0.73; p <0.01) rather than controls. However, we found no significant differences in terms of thrombus aspiration prevalence (OR: 1.88; 95%CI: 0.97-3.65; p =0.06) or door to balloon time (SMD: 0.11; 95%CI: -0.43-0.66; p =0.7). Despite that we found a significant association between COVID-19 and high mortality, more length of hospital stay and reduced post TIMI 3 score, in ACS patients after PCI, a rigorous analysis of the adjusted hazard ratio –that was absent in all the included studies- by further meta-analysis is recommended to confirm this association. However, close monitoring of COVID-19 in patients with a high risk of developing ACS, is recommended due to the associated hypercoagulability of COVID-19 infection.
No takes yet. Share an insight, caveat, or question.
El‐Qushayri et al. (2023) conducted a meta-analysis in Acute coronary syndrome undergoing percutaneous coronary intervention (n=23,225). COVID-19 infection vs. Negative controls (no COVID-19) was evaluated on Mortality rate (OR 4.95, 95% CI 3.92-6.36, p=<0.01). COVID-19 infection in ACS patients undergoing PCI was associated with a significantly higher in-hospital mortality rate compared to negative controls (OR 4.95; 95% CI 3.92-6.36; p<0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: